-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Deferred Income Tax Expense (Benefit) history and change rate from 2021 to Q2 2025.
- ELITE PHARMACEUTICALS INC /NV/ Deferred Income Tax Expense (Benefit) for the quarter ending 30 Jun 2025 was $4.88M, a 26725% increase year-over-year.
- ELITE PHARMACEUTICALS INC /NV/ annual Deferred Income Tax Expense (Benefit) for 2024 was $3.8M.
- ELITE PHARMACEUTICALS INC /NV/ annual Deferred Income Tax Expense (Benefit) for 2023 was -$20M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)
Deferred Income Tax Expense (Benefit), Annual (USD)